371 related articles for article (PubMed ID: 37828541)
21. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
22. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
[TBL] [Abstract][Full Text] [Related]
23. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
24. New insights into the gene expression associated to amyotrophic lateral sclerosis.
Recabarren-Leiva D; Alarcón M
Life Sci; 2018 Jan; 193():110-123. PubMed ID: 29241710
[TBL] [Abstract][Full Text] [Related]
25. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
26. Janus kinases to jakinibs: from basic insights to clinical practice.
Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
[TBL] [Abstract][Full Text] [Related]
27. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
29. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
30. Purinergic P2X
Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
[TBL] [Abstract][Full Text] [Related]
31. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
32. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
[TBL] [Abstract][Full Text] [Related]
33. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
34. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
Talotta R
Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
[TBL] [Abstract][Full Text] [Related]
35. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
Saini A; Chawla PA
Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.
Palomo V; Nozal V; Rojas-Prats E; Gil C; Martinez A
Br J Pharmacol; 2021 Mar; 178(6):1316-1335. PubMed ID: 32737989
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis.
Craig RA; Fox BM; Hu C; Lexa KW; Osipov M; Thottumkara AP; Larhammar M; Miyamoto T; Rana A; Kane LA; Yulyaningsih E; Solanoy H; Nguyen H; Chau R; Earr T; Kajiwara Y; Fleck D; Lucas A; Haddick PCG; Takahashi RH; Tong V; Wang J; Canet MJ; Poda SB; Scearce-Levie K; Srivastava A; Sweeney ZK; Xu M; Zhang R; He J; Lei Y; Zhuo Z; de Vicente J
J Med Chem; 2022 Dec; 65(24):16290-16312. PubMed ID: 36469401
[TBL] [Abstract][Full Text] [Related]
38. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
39. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
40. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
